The evolution of SARS-CoV-2.
Journal
Nature reviews. Microbiology
ISSN: 1740-1534
Titre abrégé: Nat Rev Microbiol
Pays: England
ID NLM: 101190261
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
accepted:
01
03
2023
medline:
18
5
2023
pubmed:
6
4
2023
entrez:
5
4
2023
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of deaths and substantial morbidity worldwide. Intense scientific effort to understand the biology of SARS-CoV-2 has resulted in daunting numbers of genomic sequences. We witnessed evolutionary events that could mostly be inferred indirectly before, such as the emergence of variants with distinct phenotypes, for example transmissibility, severity and immune evasion. This Review explores the mechanisms that generate genetic variation in SARS-CoV-2, underlying the within-host and population-level processes that underpin these events. We examine the selective forces that likely drove the evolution of higher transmissibility and, in some cases, higher severity during the first year of the pandemic and the role of antigenic evolution during the second and third years, together with the implications of immune escape and reinfections, and the increasing evidence for and potential relevance of recombination. In order to understand how major lineages, such as variants of concern (VOCs), are generated, we contrast the evidence for the chronic infection model underlying the emergence of VOCs with the possibility of an animal reservoir playing a role in SARS-CoV-2 evolution, and conclude that the former is more likely. We evaluate uncertainties and outline scenarios for the possible future evolutionary trajectories of SARS-CoV-2.
Identifiants
pubmed: 37020110
doi: 10.1038/s41579-023-00878-2
pii: 10.1038/s41579-023-00878-2
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-379Informations de copyright
© 2023. Springer Nature Limited.
Références
Khare, S. et al. GISAID’s role in pandemic response. China CDC Wkly 3, 1049–1051 (2021).
pubmed: 34934514
pmcid: 8668406
doi: 10.46234/ccdcw2021.255
Pybus, O. G. & Rambaut, A. Evolutionary analysis of the dynamics of viral infectious disease. Nat. Rev. Genet. 10, 540–550 (2009).
pubmed: 19564871
pmcid: 7097015
doi: 10.1038/nrg2583
Volz, E. et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 184, 64–75.e11 (2021).
pubmed: 33275900
pmcid: 7674007
doi: 10.1016/j.cell.2020.11.020
Clarke, D. K. et al. Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses. J. Virol. 67, 222–228 (1993).
pubmed: 8380072
pmcid: 237355
doi: 10.1128/jvi.67.1.222-228.1993
Sanjuán, R., Nebot, M. R., Chirico, N., Mansky, L. M. & Belshaw, R. Viral mutation rates. J. Virol. 84, 9733–9748 (2010).
pubmed: 20660197
pmcid: 2937809
doi: 10.1128/JVI.00694-10
Sanjuán, R. & Domingo-Calap, P. Mechanisms of viral mutation. Cell. Mol. Life Sci. 73, 4433–4448 (2016).
pubmed: 27392606
pmcid: 5075021
doi: 10.1007/s00018-016-2299-6
Loewe, L. & Hill, W. L. The population genetics of mutations: good, bad and indifferent. Philos. Trans. R. Soc. Lond. B Biol. Sci. 365, 1153–1167 (2010).
pubmed: 20308090
pmcid: 2871823
doi: 10.1098/rstb.2009.0317
Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1–23 (2015).
pubmed: 25720466
pmcid: 4369385
doi: 10.1007/978-1-4939-2438-7_1
Amicone, M. et al. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evol. Med. Public Health 10, 142–155 (2022).
pubmed: 35419205
pmcid: 8996265
doi: 10.1093/emph/eoac010
Minskaia, E., Hertzig, T., Gorbalenya, A. E. & Ziebuhr, J. Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl Acad. Sci. USA 103, 5108–5113 (2006).
pubmed: 16549795
pmcid: 1458802
doi: 10.1073/pnas.0508200103
Ribeiro, R. M. et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 8, e1002880 (2012).
pubmed: 22927816
pmcid: 3426529
doi: 10.1371/journal.ppat.1002881
Rawson, J. M. O., Landman, S. R., Reilly, C. S. & Mansky, L. M. HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. Retrovirology 12, 60 (2015).
pubmed: 26160407
pmcid: 4496919
doi: 10.1186/s12977-015-0180-6
Meng, B. et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 35, 109292 (2021).
pubmed: 34166617
pmcid: 8185188
doi: 10.1016/j.celrep.2021.109292
Malim, M. H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 675–687 (2009).
pubmed: 19038776
doi: 10.1098/rstb.2008.0185
Jarmuz, A. et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285–296 (2002).
pubmed: 11863358
doi: 10.1006/geno.2002.6718
Rogozin, I. B., Basu, M. K., Jordan, I. K., Pavlov, Y. I. & Koonin, E. V. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4, 1281–1285 (2005).
pubmed: 16082223
doi: 10.4161/cc.4.9.1994
Simmonds, P. & Ansari, M. A. Extensive C→U transition biases in the genomes of a wide range of mammalian RNA viruses; potential associations with transcriptional mutations, damage- or host-mediated editing of viral RNA. PLoS Pathog. 17, e1009596 (2021).
pubmed: 34061905
pmcid: 8195396
doi: 10.1371/journal.ppat.1009596
Klimczak, L. J., Randall, T. A., Saini, N., Li, J.-L. & Gordenin, D. A. Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic. PLoS ONE 15, e0237689 (2020).
pubmed: 33006981
pmcid: 7531822
doi: 10.1371/journal.pone.0237689
Kim, K. et al. The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness. Sci. Rep. 12, 14972 (2022).
pubmed: 36100631
pmcid: 9470679
doi: 10.1038/s41598-022-19067-x
Simmonds, P. Rampant C→U hypermutation in the genomes of SARS-CoV-2 and other coronaviruses: causes and consequences for their short- and long-term evolutionary trajectories. mSphere 5, e00408–e00420 (2020).
pubmed: 32581081
pmcid: 7316492
doi: 10.1128/mSphere.00408-20
Di Giorgio, S., Martignano, F., Torcia, M. G., Mattiuz, G. & Conticello, S. G. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci. Adv. 6, eabb5813 (2020).
pubmed: 32596474
pmcid: 7299625
doi: 10.1126/sciadv.abb5813
Ringlander, J., Fingal, J., Kann, H. & Kann, M. Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2. Proc. Natl Acad. Sci. USA 119, e2112663119 (2022).
pubmed: 35064076
pmcid: 8833170
doi: 10.1073/pnas.2112663119
van Dorp, L. et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect. Genet. Evol. 83, 104351 (2020).
pubmed: 32387564
pmcid: 7199730
doi: 10.1016/j.meegid.2020.104351
van Dorp, L. et al. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat. Commun. 11, 5986 (2020).
pubmed: 33239633
pmcid: 7688939
doi: 10.1038/s41467-020-19818-2
Belshaw, R., Sanjuán, R. & Pybus, O. G. Viral mutation and substitution: units and levels. Curr. Opin. Virol. 1, 430–435 (2011).
pubmed: 22440847
doi: 10.1016/j.coviro.2011.08.004
Rambaout, A. Estimating the rate of molecular evolution: incorporating non-contemporaneous sequences into maximum likelihood phylogenies. Bioinformatics 16, 395–399 (2000).
doi: 10.1093/bioinformatics/16.4.395
Drummond, A. Nicholls, G. K., Rodrigo, A. G. & Solomon, W. in Tools for Constructing Chronologies: Crossing Disciplinary Boundaries Vol. 177 (eds Buck, C.E. & Maillard, A.R.) 149–171 (Springer-Verlag, 2004).
Duchene, S. et al. Temporal signal and the phylodynamic threshold of SARS-CoV-2. Virus Evol. 6, veaa061 (2020).
pubmed: 33235813
pmcid: 7454936
doi: 10.1093/ve/veaa061
Ghafari, M. et al. Purifying selection determines the short-term time dependency of evolutionary rates in SARS-CoV-2 and pH1N1 influenza. Mol. Biol. Evol. 39, msac009 (2022).
pubmed: 35038728
pmcid: 8826518
doi: 10.1093/molbev/msac009
Jackson, B. et al. Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell 184, 5179–5188 (2021).
pubmed: 34499854
pmcid: 8367733
doi: 10.1016/j.cell.2021.08.014
Boni, M. F. et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat. Microbiol. 5, 1408–1417 (2020).
pubmed: 32724171
doi: 10.1038/s41564-020-0771-4
Lai, M. M. & Cavanagh, D. The molecular biology of corona viruses. Adv. Virus Res. 48, 1–100 (1997).
pubmed: 9233431
pmcid: 7130985
doi: 10.1016/S0065-3527(08)60286-9
Rambaut, A. et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563/1 (2020).
O’Toole, Á. et al. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with Grinch. Wellcome Open Res. 6, 121 (2021).
pubmed: 34095513
pmcid: 8176267
Sekizuka, T. et al. Genome recombination between the Delta and Alpha variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Jpn J. Infect. Dis. 75, 415–418 (2022).
pubmed: 35228502
doi: 10.7883/yoken.JJID.2021.844
UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England — Technical Briefing 39. GOV.UK https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf (2022).
UK Health Security Agency (UKHSA). SARS-CoV-2 variants of public health interest: 28 October 2022. GOV.UK https://www.gov.uk/government/publications/sars-cov-2-variants-of-public-health-interest/sars-cov-2-variants-of-public-health-interest-28-october-2022 (2022).
Rhee, C., Kanjilal, S., Baker, M. & Klompas, M. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin. Infect. Dis. 72, 1467–1474 (2021).
pubmed: 33029620
doi: 10.1093/cid/ciaa1249
Bullard, J. et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin. Infect. Dis. 71, 2663–2666 (2020).
pubmed: 32442256
doi: 10.1093/cid/ciaa638
Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).
pubmed: 32235945
doi: 10.1038/s41586-020-2196-x
Kissler, S. M. et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. N. Engl. J. Med. 385, 2489–2491 (2021).
pubmed: 34941024
doi: 10.1056/NEJMc2102507
Sun, K. et al. SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts. Sci. Transl Med. 14, eabo7081 (2022).
pubmed: 35638937
doi: 10.1126/scitranslmed.abo7081
Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2, e13–e22 (2021).
pubmed: 33521734
doi: 10.1016/S2666-5247(20)30172-5
Hakki, S. et al. Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study. Lancet Respir. Med. 10, 1061–1073 (2022).
pubmed: 35988572
pmcid: 9388060
doi: 10.1016/S2213-2600(22)00226-0
Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. Science 372, eabg0821 (2021).
pubmed: 33688063
pmcid: 8128293
doi: 10.1126/science.abg0821
Ke, R. et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat. Microbiol. 7, 640–652 (2022).
pubmed: 35484231
pmcid: 9084242
doi: 10.1038/s41564-022-01105-z
Farjo, M. et al. Within-host evolutionary dynamics and tissue compartmentalization during acute SARS-CoV-2 infection. Preprint at bioRxiv https://doi.org/10.1101/2022.06.21.497047 (2022).
doi: 10.1101/2022.06.21.497047
Martin, M. A. & Koelle, K. Comment on ‘Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2’. Sci. Transl Med. 13, eabh1803 (2021).
pubmed: 34705523
pmcid: 9301528
doi: 10.1126/scitranslmed.abh1803
Koelle, K. et al. Masks do not more than prevent transmission: theory and data undermine the variolation hypothesis. Preprint at medRxiv https://doi.org/10.1101/2022.06.28.22277028 (2022).
doi: 10.1101/2022.06.28.22277028
pubmed: 36203549
pmcid: 9536058
Lumby, C. K., Nene, N. R. & Illingworth, C. J. R. A novel framework for inferring parameters on transmission from viral sequence data. PLoS Genet. 14, e1007718 (2018).
pubmed: 30325921
pmcid: 6203404
doi: 10.1371/journal.pgen.1007718
Zwart, M. P. & Elena, S. F. Matters of size: genetic bottlenecks in virus infection and their potential impact on evolution. Annu. Rev. Virol. 2, 161–179 (2015).
pubmed: 26958911
doi: 10.1146/annurev-virology-100114-055135
McCrone, J. T. et al. Stochastic processes constrain the within and between host evolution of influenza virus. eLife 7, 35962 (2018).
doi: 10.7554/eLife.35962
Sobel Leonard, A., Weissman, D. B., Greenbaum, B., Ghedin, E. & Koelle, K. Transmission bottleneck size estimation from pathogen deep-sequencing data, with an application to human influenza A virus. J. Virol. 91, 00171-17 (2017).
doi: 10.1128/JVI.00171-17
Ghafari, M., Lumpy, C. K., Weissman, D. B. & Illingworth, C. J. R. Inferring transmission bottleneck size from viral sequence data using a novel haplotype reconstruction method. J. Virol. 94, e00014–e00020 (2020).
pubmed: 32295920
pmcid: 7307158
doi: 10.1128/JVI.00014-20
Joseph, S. B., Swanstrom, R., Kashuba, A. D. M. & Cohen, M. S. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat. Rev. Microbiol. 13, 414–425 (2015).
pubmed: 26052661
pmcid: 4793885
doi: 10.1038/nrmicro3471
Gutiérrez, S., Michalakis, Y. & Blanc, S. Virus population bottlenecks during within-host progression and host-to-host transmission. Curr. Opin. Virol. 2, 546–555 (2012).
pubmed: 22921636
doi: 10.1016/j.coviro.2012.08.001
Adam, D. C. et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nat. Med. 26, 1714–1719 (2020).
pubmed: 32943787
doi: 10.1038/s41591-020-1092-0
Liu, Y., Eggo, R. M. & Kucharski, A. J. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet 395, e47 (2020).
pubmed: 32113505
pmcid: 7158947
doi: 10.1016/S0140-6736(20)30462-1
Wright, S. Evolution in Mendelian populations. Genetics 16, 97–159 (1931).
pubmed: 17246615
pmcid: 1201091
doi: 10.1093/genetics/16.2.97
Grubaugh, N. D., Hanage, W. P. & Rasmussen, A. L. Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell 182, 794–795 (2020).
pubmed: 32697970
pmcid: 7332445
doi: 10.1016/j.cell.2020.06.040
Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827.e19 (2020).
pubmed: 32697968
pmcid: 7332439
doi: 10.1016/j.cell.2020.06.043
Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020).
pubmed: 33184236
pmcid: 7775736
doi: 10.1126/science.abe8499
Meyer, A. G., Spielman, S. J., Bedford, T. & Wilke, C. O. Time dependence of evolutionary metrics during the 2009 pandemic influenza virus outbreak. Virus Evol. 1, vev006 (2015).
pubmed: 26770819
pmcid: 4710376
doi: 10.1093/ve/vev006
Holmes, E. C., Dudas, G., Rambaut, A. & Andersen, K. G. The evolution of Ebola virus: insights from the 2013–2016 epidemic. Nature 538, 193–200 (2016).
pubmed: 27734858
pmcid: 5580494
doi: 10.1038/nature19790
Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022).
pubmed: 35042229
pmcid: 8942855
doi: 10.1038/s41586-022-04411-y
Lythgoe, K. A. et al. Lineage replacement and evolution captured by the United Kingdom Covid Infection Survey. Preprint at medRxiv https://doi.org/10.1101/2022.01.05.21268323 (2022).
doi: 10.1101/2022.01.05.21268323
Tay, J. H., Porter, A. F., Wirth, W. & Duchene, S. The emergence of SARS-CoV-2 variants of concern is driven by acceleration of the substitution rate. Mol. Biol. Evol. 39, msac013 (2022).
pubmed: 35038741
pmcid: 8807201
doi: 10.1093/molbev/msac013
Gräf, T. et al. Identification of a novel SARS-CoV-2 P.1 sub-lineage in Brazil provides new insights about the mechanisms of emergence of variants of concern. Virus Evol. 7, veab091 (2021).
pubmed: 35039782
pmcid: 8754780
doi: 10.1093/ve/veab091
Neher, R. A. Contributions of adaptation and purifying selection of SARS-CoV-2 evolution. Virus Evol. 8, veac113 (2022).
doi: 10.1093/ve/veac113
Saito, A. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe 30, 1540–1555 (2022).
pubmed: 36272413
pmcid: 9578327
doi: 10.1016/j.chom.2022.10.003
Ito, J. et al. Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Preprint at bioRxiv https://doi.org/10.1101/2022.12.05.519085 (2022).
doi: 10.1101/2022.12.05.519085
Sousa, W. P. & Grosholz, E. D. in Habitat Structure Vol. 8 (eds Bell, S. S., McCoy, E. D. & Mushinsky, H. R.) 300–324 (Springer, 1991).
Hilleman, M. R. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc. Natl Acad. Sci. USA 101, 14560–14566 (2004).
pubmed: 15297608
pmcid: 521982
doi: 10.1073/pnas.0404758101
Domingo, E. in Virus as Populations Ch. 5 (ed. Domingo, E.) 167–194 (Academic, 2020).
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).
pubmed: 32225175
pmcid: 7328981
doi: 10.1038/s41586-020-2179-y
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Sinha, S., Tam, B. & Ming Wang, S. RBD double mutations of SARS-CoV-2 strains increase transmissibility through enhanced interaction between RBD and ACE2 receptor. Viruses 14, 1 (2022).
doi: 10.3390/v14010001
Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739–751 (2020).
pubmed: 32991842
pmcid: 7492024
doi: 10.1016/j.cell.2020.09.032
Ozono, S. et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun. 12, 848 (2021).
pubmed: 33558493
pmcid: 7870668
doi: 10.1038/s41467-021-21118-2
Liu, H. et al. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell Res. 31, 720–722 (2021).
pubmed: 33893398
pmcid: 8063779
doi: 10.1038/s41422-021-00496-8
Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020).
pubmed: 32942285
pmcid: 7116727
doi: 10.1038/s41586-020-2772-0
Peacock, T. P. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 6, 899–909 (2021).
pubmed: 33907312
doi: 10.1038/s41564-021-00908-w
Wrobel, A. G. et al. Evolution of the SARS-CoV-2 spike protein in the human host. Nat. Commun. 13, 1178 (2022).
pubmed: 35246509
pmcid: 8897445
doi: 10.1038/s41467-022-28768-w
Johnson, B. A. et al. Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. PLoS Pathog. 18, e1010627 (2022).
pubmed: 35728038
pmcid: 9275689
doi: 10.1371/journal.ppat.1010627
Thorne, L. G. et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature 602, 487–495 (2022).
pubmed: 34942634
doi: 10.1038/s41586-021-04352-y
Lamers, M. M. et al. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium. Preprint at bioRxiv https://doi.org/10.1101/2022.01.19.476898 (2022).
doi: 10.1101/2022.01.19.476898
Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715–720 (2022).
pubmed: 35104836
doi: 10.1038/s41586-022-04479-6
Port, J. et al. Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo. Nat. Microbiol. 7, 213–223 (2022).
pubmed: 35017676
doi: 10.1038/s41564-021-01047-y
Bushmaker, T. et al. Comparative aerosol and surface stability of SARS-CoV-2 variants of concern. Preprint at bioRxiv https://doi.org/10.1101/2022.11.21.517352 (2022).
doi: 10.1101/2022.11.21.517352
pubmed: 36451892
pmcid: 9709801
Oswin, H. P., Haddrell, A. E., Otern-Fernandez, M. & Reid, J. P. The dynamics of SARS-CoV-2 infectivity with changes in aerosol microenvironment. Proc. Natl Acad. Sci. USA 119, e2200109119 (2022).
pubmed: 35763573
pmcid: 9271203
doi: 10.1073/pnas.2200109119
King, A. A., Schresta, S., Harvill, E. T. & Bjornstad, O. N. Evolution of acute infections and the invasion‐persistence trade‐off. Am. Nat. 173, 446–455 (2009).
pubmed: 19231966
pmcid: 4101379
doi: 10.1086/597217
Lehtinen, S., Ashcroft, P. & Bonhoeffer, S. On the relationship between serial interval, infectiousness profile and generation time. J. R. Soc. Interface 18, 20200756 (2021).
pubmed: 33402022
pmcid: 7879757
doi: 10.1098/rsif.2020.0756
Wallinga, J. & Lipsitch, M. How generation intervals shape the relationship between growth rates and reproductive numbers. Proc. Biol. Sci. 274, 599–604 (2007).
pubmed: 17476782
Backer, J. A. et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021. Eur. Surveill. 27, 2200042 (2022).
doi: 10.2807/1560-7917.ES.2022.27.6.2200042
Hay, J. A. et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and1 infection rebound: a retrospective cohort study. eLife 11, e81849 (2022).
pubmed: 36383192
pmcid: 9711520
doi: 10.7554/eLife.81849
Pulliam, J. R. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 376, 596 (2022).
doi: 10.1126/science.abn4947
Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409–424 (2021).
pubmed: 34075212
pmcid: 8167834
doi: 10.1038/s41579-021-00573-0
Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310.e20 (2020).
pubmed: 32841599
pmcid: 7418704
doi: 10.1016/j.cell.2020.08.012
Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57.e9 (2021).
pubmed: 33259788
pmcid: 7676316
doi: 10.1016/j.chom.2020.11.007
Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484.e15 (2022).
pubmed: 35081335
pmcid: 8723827
doi: 10.1016/j.cell.2021.12.046
McCallum, M. et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 375, 864–868 (2022).
pubmed: 35076256
pmcid: 9427005
doi: 10.1126/science.abn8652
Nutalai, R. et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell 185, 2116–2131.e18 (2022).
pubmed: 35662412
pmcid: 9120130
doi: 10.1016/j.cell.2022.05.014
Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422–2433.e13 (2022).
pubmed: 35772405
pmcid: 9181312
doi: 10.1016/j.cell.2022.06.005
Kistler, K. E., Huddleston, J. & Bedford, T. Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. Cell Host Microbe 30, 545–555.e4 (2022).
pubmed: 35364015
pmcid: 8938189
doi: 10.1016/j.chom.2022.03.018
Obermeyer, F. et al. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science 376, 1327–1332 (2022).
pubmed: 35608456
doi: 10.1126/science.abm1208
Naranbhai, V. et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell 185, 1041–1051 (2022).
pubmed: 35202566
pmcid: 8810349
doi: 10.1016/j.cell.2022.01.029
Yu, F., Tai, W. & Cheng, G. T-cell immunity: a barrier to Omicron immune evasion. Sig. Transduct. Target. Ther. 7, 297 (2022).
doi: 10.1038/s41392-022-01142-4
Riu, C. et al. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Sci. Transl Med. 14, eabj6824 (2022).
doi: 10.1126/scitranslmed.abj6824
Dolton, G. et al. Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell 185, 2936–2951 (2022).
pubmed: 35931021
pmcid: 9279490
doi: 10.1016/j.cell.2022.07.002
Agerer, B. et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8
doi: 10.1126/sciimmunol.abg6461
Chang, M. R. et al. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. eBioMedicine 80, 104025 (2022).
pubmed: 35533497
pmcid: 9073271
doi: 10.1016/j.ebiom.2022.104025
Tada, T. et al. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. iScience 24, 103341 (2021).
pubmed: 34723159
pmcid: 8541826
doi: 10.1016/j.isci.2021.103341
Reed, A. F. The evolution of virulence. Trends Microbiol. 2, 73–76 (1994).
doi: 10.1016/0966-842X(94)90537-1
Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021).
pubmed: 33690265
doi: 10.1038/s41586-021-03402-9
Funk, T. et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eur. Surveill. 26, 2100348 (2021).
doi: 10.2807/1560-7917.ES.2021.26.16.2100348
Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 16 2021. GOV.UK https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16.pdf (2021).
European Centre for Disease Prevention and Control. Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU/EEA, 19th update. ECDC https://www.ecdc.europa.eu/en/publications-data/covid-19-omicron-risk-assessment-further-emergence-and-potential-impact (2022).
Barut, G. T. et al. The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype. Nat. Commun. 13, 5929 (2022).
pubmed: 36207334
pmcid: 9543931
doi: 10.1038/s41467-022-33632-y
Chen, D.-Y. et al. Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. Nature 615, 143–150 (2023).
pubmed: 36630998
doi: 10.1038/s41586-023-05697-2
Liu, S., Selvaraj, P., Sangare, K., Luan, B. & Wang, T. T. Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice. Cell Rep. 40, 111359 (2022).
pubmed: 36075211
pmcid: 9420700
doi: 10.1016/j.celrep.2022.111359
Markov, P. V., Katzourakis, A. & Stilianakis, N. I. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. Nat. Rev. Microbiol. 20, 251–252 (2022).
pubmed: 35288685
pmcid: 8919145
doi: 10.1038/s41579-022-00722-z
Elsworth, P. et al. Increased virulence of rabbit haemorrhagic disease virus associated with genetic resistance in wild Australian rabbits (Oryctolagus cuniculus). Virology 464–465, 415–423 (2014).
pubmed: 25146599
doi: 10.1016/j.virol.2014.06.037
Lange, M. & Thulke, H.-H. Elucidating transmission parameters of African swine fever through wild boar carcasses by combining spatio-temporal notification data and agent-based modelling. Stoch. Environ. Res. Risk Assess. 31, 379–391 (2017).
doi: 10.1007/s00477-016-1358-8
World Health Organization (WHO). WHO Middle East respiratory syndrome: global summary and assessment of risk — 16 November 2022. WHO https://www.who.int/publications/i/item/WHO-MERS-RA-2022.1 (2022).
COVID-19 excess mortality collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet 399, 1513–1536 (2022).
doi: 10.1016/S0140-6736(21)02796-3
Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021).
pubmed: 33658326
pmcid: 8128288
doi: 10.1126/science.abg3055
Shen, X. et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529–539.e3 (2021).
pubmed: 33705729
pmcid: 7934674
doi: 10.1016/j.chom.2021.03.002
Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403–1407 (2020).
pubmed: 32669681
pmcid: 7610519
doi: 10.1038/s41564-020-0770-5
Konings, F. et al. SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse. Nat. Microbiol. 6, 821–823 (2021).
pubmed: 34108654
doi: 10.1038/s41564-021-00932-w
Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021).
pubmed: 33853970
pmcid: 8139423
doi: 10.1126/science.abh2644
Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361.e6 (2021).
pubmed: 33730597
pmcid: 7901269
doi: 10.1016/j.cell.2021.02.037
Sabino, E. C. et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 397, 452–455 (2021).
pubmed: 33515491
pmcid: 7906746
doi: 10.1016/S0140-6736(21)00183-5
Dhar, M. S. et al. Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science 374, 995–999 (2021).
pubmed: 34648303
pmcid: 7612010
doi: 10.1126/science.abj9932
Bolze, A. et al. SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads. Cell Rep. Med. 3, 100564 (2022).
pubmed: 35474739
pmcid: 8922438
doi: 10.1016/j.xcrm.2022.100564
Campbell, F. et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eur. Surveill. 26, 2100509 (2021).
doi: 10.2807/1560-7917.ES.2021.26.24.2100509
Tegally, H. et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. 28, 1785–1790 (2022).
pubmed: 35760080
pmcid: 9499863
doi: 10.1038/s41591-022-01911-2
Attwood, S. W., Hill, S. C., Aanensen, D. M., Connor, T. R. & Pybus, O. G. Phylogenetic and phylodynamic approaches to understanding and combating the early SARS-CoV-2 pandemic. Nat. Rev. Genet. 23, 547–562 (2022).
pubmed: 35459859
pmcid: 9028907
doi: 10.1038/s41576-022-00483-8
Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757–773 (2021).
pubmed: 34535792
pmcid: 8447121
doi: 10.1038/s41576-021-00408-x
Hill, V. et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. 8, veac080 (2022).
pubmed: 36533153
pmcid: 9752794
doi: 10.1093/ve/veac080
McCrone, J. T. et al. Context-specific emergence and growth of the SARS-CoV-2 Delta variant. Nature 610, 154–160 (2022).
pubmed: 35952712
pmcid: 9534748
doi: 10.1038/s41586-022-05200-3
Adepoju, P. Challenges of SARS-CoV-2 genomic surveillance in Africa. Lancet Microbe 2, e139 (2021).
pubmed: 33817677
pmcid: 8009639
doi: 10.1016/S2666-5247(21)00065-3
Wilkinson, E. et al. A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science 374, 423–431 (2021).
pubmed: 34672751
pmcid: 7613315
doi: 10.1126/science.abj4336
Mandolo, J. et al. SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. BMC Med. 19, 303 (2021).
pubmed: 34794434
pmcid: 8601780
doi: 10.1186/s12916-021-02187-y
Ghafari, M., Watson, O. J., Karlinsky, A., Ferretti, L. & Katzourakis, A. A framework for reconstructing SARS-CoV-2 transmission dynamics using excess mortality data. Nat. Commun. 13, 3015 (2022).
pubmed: 35641529
pmcid: 9156676
doi: 10.1038/s41467-022-30711-y
Ghafari, M., Liu, Q., Dhillon, A., Katzourakis, A. & Weissman, D. B. Investigating the evolutionary origins of the first three SARS-CoV-2 variants of concern. Front. Virol. 2, 942555 (2022).
doi: 10.3389/fviro.2022.942555
Schlottau, K. et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe 1, e218–e225 (2020).
pubmed: 32838346
pmcid: 7340389
doi: 10.1016/S2666-5247(20)30089-6
Muñoz-Fontela, C. et al. Advances and gaps in SARS-CoV-2 infection models. PLoS Pathog. 18, e1010161 (2022).
pubmed: 35025969
pmcid: 8757994
doi: 10.1371/journal.ppat.1010161
Oude Munnink, B. B. et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science 371, 172–177 (2021).
pubmed: 33172935
doi: 10.1126/science.abe5901
Hale, V. L. et al. SARS-CoV-2 infection in free-ranging white-tailed deer. Nature 602, 481–486 (2022).
pubmed: 34942632
doi: 10.1038/s41586-021-04353-x
Ren, W. et al. Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption. PLoS Pathog. 17, e1010053 (2021).
pubmed: 34748603
pmcid: 8601601
doi: 10.1371/journal.ppat.1010053
Pickering, B. et al. Divergent SARS-CoV-2 variant emerges in white-tailed deer with deer-to-human transmission. Nat. Microbiol. 7, 2011–2024 (2022).
pubmed: 36357713
pmcid: 9712111
doi: 10.1038/s41564-022-01268-9
Porter, A. F., Purcell, D. F. J., Howden, B. P. & Duchene, S. Evolutionary rate of SARS-CoV-2 increases during zoonotic infection of farmed mink. Virus Evol. 9, vead002 (2023).
pubmed: 36751428
pmcid: 9896948
doi: 10.1093/ve/vead002
Diamond, M. et al. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Preprint at Res. Sq. https://doi.org/10.21203/rs.3.rs-1211792/v1 (2021).
doi: 10.21203/rs.3.rs-1211792/v1
pubmed: 34981044
pmcid: 8722607
Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693–699 (2022).
pubmed: 35062016
doi: 10.1038/s41586-022-04442-5
Dinnon, K. H. III et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560–566 (2020).
pubmed: 32854108
pmcid: 8034761
doi: 10.1038/s41586-020-2708-8
Weigang, S. et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat. Commun. 12, 6405 (2021).
pubmed: 34737266
pmcid: 8568958
doi: 10.1038/s41467-021-26602-3
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A. & Padera, R. F. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 383, 2291–2293 (2020).
pubmed: 33176080
doi: 10.1056/NEJMc2031364
Clark, S. A. et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell 184, 2605–2617.e18 (2021).
pubmed: 33831372
pmcid: 7962548
doi: 10.1016/j.cell.2021.03.027
Msomi, N., Lessells, R., Mlisana, K. & de Oliveira, T. Africa: tackle HIV and COVID-19 together. Nature 600, 33–36 (2021).
pubmed: 34853449
doi: 10.1038/d41586-021-03546-8
Wilkinson, S. A. J. et al. Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol. 8, veac050 (2022).
pubmed: 35996593
pmcid: 9384748
doi: 10.1093/ve/veac050
Gregory, D. A. et al. Genetic diversity and evolutionary convergence of cryptic SARS- CoV-2 lineages detected via wastewater sequencing. PLoS Pathog. 18, e1010636 (2022).
pubmed: 36240259
pmcid: 9604950
doi: 10.1371/journal.ppat.1010636
Gonzalez-Reiche, A. S. et al. SARS-CoV-2 variants in the making: sequential intrahost evolution and forward transmissions in the context of persistent infections. Preprint at bioRxiv https://doi.org/10.1101/2022.05.25.22275533 (2022).
doi: 10.1101/2022.05.25.22275533
pubmed: 36299428
pmcid: 9603824
Harari, S. et al. Drivers of adaptive evolution during chronic SARS-CoV-2 infections. Nat. Med. 28, 1501–1508 (2022).
pubmed: 35725921
pmcid: 9307477
doi: 10.1038/s41591-022-01882-4
Moran, E. et al. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infect. Dis. 21, 1345–1347 (2021).
pubmed: 34411531
pmcid: 8367192
doi: 10.1016/S1473-3099(21)00464-3
Dennehy, J. J., Gupta, R. K., Hanage, W. P., Johnson, M. C. & Peacock, T. P. Where is the next SARS-CoV-2 variant of concern? Lancet 399, 1938–1939 (2022).
pubmed: 35598619
pmcid: 9119661
doi: 10.1016/S0140-6736(22)00743-7
Lemieux, J. E. & Luban, J. Consulting the Oracle of SARS-CoV-2 infection. J. Infec. Dis. 225, 1115–1117 (2022).
doi: 10.1093/infdis/jiab623
Oude Munnink, B. B. et al. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nat. Med. 27, 1518–1524 (2021).
pubmed: 34504335
doi: 10.1038/s41591-021-01472-w
Maher, M. C. et al. Predicting the mutational drivers of future SARS-CoV-2 variants of concern. Sci. Transl Med. 14, eabk3445 (2022).
pubmed: 35014856
doi: 10.1126/scitranslmed.abk3445
Subissi, L. et al. An early warning system for emerging SARS-CoV-2 variants. Nat. Med. 28, 1110–1115 (2022).
pubmed: 35637337
doi: 10.1038/s41591-022-01836-w
Telenti, A., Hodcroft, E. B. & Robertson, D. L. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb. Perspect. Med. 12, a041390 (2022).
pubmed: 35444005
doi: 10.1101/cshperspect.a041390
Amman, F. et al. Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale. Nat. Biotechnol. 40, 1814–1822 (2022).
pubmed: 35851376
doi: 10.1038/s41587-022-01387-y
Karthikeyan, S. et al. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature 609, 101–108 (2022).
pubmed: 35798029
pmcid: 9433318
doi: 10.1038/s41586-022-05049-6
Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28, 472–476 (2022).
pubmed: 35042228
pmcid: 8938268
doi: 10.1038/s41591-022-01700-x
Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488–492 (2022).
pubmed: 35102311
pmcid: 8930768
doi: 10.1038/s41586-022-04460-3
Kitchin, D. et al. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. Cell Rep. Med. 3, 100535 (2022).
pubmed: 35474744
pmcid: 8828412
doi: 10.1016/j.xcrm.2022.100535
He, W.-T. et al. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nat. Immunol. 23, 960–970 (2022).
pubmed: 35654851
pmcid: 10083051
doi: 10.1038/s41590-022-01222-1
Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 1461–1467 (2022).
pubmed: 35614233
pmcid: 9307472
doi: 10.1038/s41591-022-01840-0
Lavine, J. S., Bjornstad, O. N. & Antia, R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 371, 741–745 (2021).
pubmed: 33436525
pmcid: 7932103
doi: 10.1126/science.abe6522
Calaway, E. Heavily mutated Omictorn varaints puts scientists into alert. Nature 600, 21 (2021).
doi: 10.1038/d41586-021-03552-w
Pensaert, M., Callebaut, P. & Vergote, J. Isolation of a porcine respiratory, non-enteric coronavirus related to transmissible gastroenteritis. Vet. Q. 8, 257–261 (1986).
pubmed: 3018993
doi: 10.1080/01652176.1986.9694050
Katzourakis, A. COVID-19: endemic doesn’t mean harmless. Nature 601, 485 (2022).
pubmed: 35075305
doi: 10.1038/d41586-022-00155-x
Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121–4123 (2018).
pubmed: 29790939
pmcid: 6247931
doi: 10.1093/bioinformatics/bty407
Stilianakis, N. I., Perelson, A. S. & Hayden, F. G. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J. Infect. Dis. 177, 863–873 (1998).
pubmed: 9534957
doi: 10.1086/515246
Clavel, F. & Hance, A. J. HIV drug resistance. N. Engl. J. Med. 350, 1023–1035 (2004).
pubmed: 14999114
doi: 10.1056/NEJMra025195
Holmes, E. C. et al. Understanding the impact of resistance to influenza antivirals. Clin. Microbiol. Rev. 34, e00224-20 (2021).
pubmed: 33568554
pmcid: 7950363
doi: 10.1128/CMR.00224-20
Artese, A. et al. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist. Updat. 53, 100721 (2020).
pubmed: 33132205
pmcid: 7448791
doi: 10.1016/j.drup.2020.100721
Hussain, M., Galvin, H. D., Haw, T. Y., Nutsford, A. N. & Husain, M. Drug resistance in influenza A virus: the epidemiology and management. Infect. Drug Resist. 10, 121–134 (2017).
pubmed: 28458567
pmcid: 5404498
doi: 10.2147/IDR.S105473
Perelson, A. S., Rong, L. & Hayden, F. G. Combination antiviral therapy for influenza: predictions from modeling of human infections. J. Infect. Dis. 205, 1642–1645 (2012).
pubmed: 22448006
pmcid: 3415857
doi: 10.1093/infdis/jis265
Dunning, J., Baillie, J. K., Cao, B. & Hayden, F. G. International severe acute respiratory and emerging infection consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect. Dis. 14, 1259–1270 (2014).
pubmed: 25213733
pmcid: 7164787
doi: 10.1016/S1473-3099(14)70821-7
Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N. Engl. J. Med. 386, 1397–1408 (2022).
pubmed: 35172054
doi: 10.1056/NEJMoa2118542
Jeong, J. H. et al. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. Antivir. Res. 208, 105430 (2022).
pubmed: 36209984
doi: 10.1016/j.antiviral.2022.105430
National Institues of Health (NIH). Antiviral agents, including antibody products. NIH.GOV https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/summary-recommendations/ (2023).
Szemiel, A. M. et al. In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 17, e1009929 (2021).
pubmed: 34534263
pmcid: 8496873
doi: 10.1371/journal.ppat.1009929
Stevens, L. J. et al. Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci. Transl Med. 14, eabo0718 (2022).
pubmed: 35482820
doi: 10.1126/scitranslmed.abo0718
Zhou, Y. et al. Nirmatrelvir resistant SARS-CoV-2 variants with high fitness in vitro. Sci. Adv. 8, eadd7197 (2022).
pubmed: 36542720
pmcid: 9770952
doi: 10.1126/sciadv.add7197
Malone, B. & Campbell, E. A. Molnupiravir: coding for catastrophe. Nat. Struct. Mol. Biol. 28, 706–708 (2021).
pubmed: 34518697
doi: 10.1038/s41594-021-00657-8
Pillai, S. K., Wong, J. K. & Barbour, J. D. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 5, 26 (2008).
pubmed: 18339206
pmcid: 2323022
doi: 10.1186/1742-4690-5-26
Donovan-Banfield, I. et al. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE phase IIa clinical trial. Nat. Commun. 13, 7284 (2022).
pubmed: 36435798
pmcid: 9701236
doi: 10.1038/s41467-022-34839-9
Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Ansino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344–348 (2006).
pubmed: 16327776
doi: 10.1038/nature04388
Pfeiffer, J. K. & Kirkegaard, K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 1, e11 (2005).
pubmed: 16220146
pmcid: 1250929
doi: 10.1371/journal.ppat.0010011
Sanderson, T., Hisner, R., Donovan-Banfield, I., Peackock, T. & Ruis, C. Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases. Preprint at medRxiv https://doi.org/10.1101/2023.01.26.23284998 (2023).
doi: 10.1101/2023.01.26.23284998
pubmed: 36865116
pmcid: 9980223
Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393.e12 (2021).
pubmed: 33794143
pmcid: 7980144
doi: 10.1016/j.cell.2021.03.036
Focosi, D. et al. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect. Dis. 22, e311–e326 (2022).
pubmed: 35803289
pmcid: 9255948
doi: 10.1016/S1473-3099(22)00311-5
Choudhary, M. C. et al. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat. Microbiol. 7, 1906–1917 (2022).
pubmed: 36289399
pmcid: 9675946
doi: 10.1038/s41564-022-01254-1
Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632–644 (2021).
pubmed: 33475701
pmcid: 7821080
doi: 10.1001/jama.2021.0202
Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).
pubmed: 34234131
pmcid: 8263750
doi: 10.1038/s41467-021-24435-8
Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021).
pubmed: 33664494
pmcid: 8058618
doi: 10.1038/s41591-021-01294-w
Corman, V. M., Muth, D., Niemeyer, D. & Drosten, C. Hosts and sources of endemic human coronaviruses. Adv. Virus Res. 100, 163–188 (2018).
pubmed: 29551135
pmcid: 7112090
doi: 10.1016/bs.aivir.2018.01.001
Cui, J., Li, F. & Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181–192 (2019).
pubmed: 30531947
doi: 10.1038/s41579-018-0118-9
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y. & Yuen, K. Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20, 660–694 (2007).
pubmed: 17934078
pmcid: 2176051
doi: 10.1128/CMR.00023-07
Kiyuka, P. K. et al. Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. J. Infect. Dis. 217, 1728–1739 (2018).
pubmed: 29741740
doi: 10.1093/infdis/jiy098
Larson, H. E., Reed, S. E. & Tyrrell, D. A. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. J. Med. Virol. 5, 221–229 (1980).
pubmed: 6262450
pmcid: 7167084
doi: 10.1002/jmv.1890050306
Vijgen, L. et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. 79, 1595–1604 (2005).
pubmed: 15650185
pmcid: 544107
doi: 10.1128/JVI.79.3.1595-1604.2005
Pollett, S. et al. A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic. Sci. Rep. 11, 17365 (2021).
pubmed: 34462471
pmcid: 8405798
doi: 10.1038/s41598-021-96626-8
Akaishi, T. Insertion-and-deletion mutations between the genomes of SARS-CoV, SARS-CoV-2, and bat coronavirus RaTG13. Microbiol. Spectr. 10, e0071622 (2022).
pubmed: 35658573
doi: 10.1128/spectrum.00716-22
Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 176, 104742 (2020).
pubmed: 32057769
doi: 10.1016/j.antiviral.2020.104742
Ren, W. et al. Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J. Virol. 82, 1899–1907 (2008).
pubmed: 18077725
doi: 10.1128/JVI.01085-07
Guo, H. et al. Identification of a novel lineage bat SARS-related coronaviruses that use bat ACE2 receptor. Emerg. Microbes Infect. 10, 1507–1514 (2021).
pubmed: 34263709
pmcid: 8344244
doi: 10.1080/22221751.2021.1956373
Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303, 1666–1669 (2004).
doi: 10.1126/science.1092002